bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Authors: Wijewarnasuriya Dinali , Bebernitz Christina , Lopez Andrea V. , Rafiq Sarwish , Brentjens Renier J.
Published: April 2023

(A) Media from in vitro co-culture of CAR T cells with EL4mCD19 tumor cells was assessed for IL12p70 on day 7 after CAR T cell treatment. Data shown is mean +/- s.e.m. of two independent experiments. (B) EL4mCD19 tumor bearing C57BL/6 mice, pretreated with 250mg/kg per mouse of cyclophosphamide day -3, treated i.v. with CAR T cells day 0. Significance determined bylong-rank Mantel-Cox Test, with 95% confidence interval (n=3 per group). *p=0.0224 m1928ï�º compared to m1928ï�º + cyclophosphamide and *p=0.0295 m19ï�º compared to m19ï�º + cyclophosphamide (C) Flow cytometry demonstrating CD25 expression on CAR T cells prior to injection in terms of percentage and representative flow cytometry plot (ns by ordinary one-way ANOVA). Data shown is mean +/- s.e.m. of three independent experiments (n=3 per group). (D) CAR T cells were co-cultured with EL4mCD19 tumor cells and assessed for cytotoxicity 4 hours later, using a luciferase killing assay. m1928ï�º, m19ï�ºIL-12, and m1928ï�ºIL-12 CAR T cells showed significantly increased cytotoxicity compared to m19ï�º CAR T cells at E:T ratios of 2:1, 1:1, and 0.5:1. There was no difference in tumor lysis between 19ï�º12 and m1928ï�ºIL-12 CAR T cells (*p=<0.001 by two-way ANOVA). Data shown is mean +/- s.e.m. of three independent experiments. Serum was obtained through retro-orbital bleeds and assessed for IL12p70 through luminex on day 7 after CAR T cell treatment. Data shown is mean +/- s.e.m. of three independent
Legend for the Supplementary Figures and Tables from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Authors: Han Jiefei , Duan Jianchun , Bai Hua , Wang Yuqi , Wan Rui , Wang Xin , Chen Si , Tian Yanhua , Wang Di , Fei Kailun , Yao Zhuoran , Wang Shuhang , Lu Zhimin , Wang Zhijie , Wang Jie
Published: April 2023

Legend for the Supplementary Figures and Tables
Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
Authors: Peeters Marlies J.W. , Dulkeviciute Donata , Draghi Arianna , Ritter Cathrin , Rahbech Anne , Skadborg Signe K. , Seremet Tina , Carnaz Simões Ana Micaela , Martinenaite Evelina , Halldórsdóttir Hólmfridur R. , Andersen Mads Hald , Olofsson Gitte Holmen , Svane Inge Marie , Rasmussen Lene Juel , Met Özcan , Becker Jürgen C. , Donia Marco , Desler Claus , thor Straten Per
Published: April 2023

Supplementary Methods. Table S1: primer sequences. Figure S1: PROS1 and MERTK co-expression on 3-day activated CD8+ T cells. Figure S2: TAM receptors TYRO3 and AXL are nearly absent or absent on CD8+ T cells. Figure S3: Phosphatidylserine is not a limiting factor for TAM signaling in CD8+ T cell cultures and is partly non-apoptotic. Figure S4: Bioenergetic properties of PROS1-supplemented cells. Figure S5: PROS1 consumption by cancer cells and T cells affects TIL-mediated killing.
Table S1 from A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy
Authors: Liu Si-Qi , Grantham Alyssa , Landry Casey , Granda Brian , Chopra Rajiv , Chakravarthy Srinivas , Deutsch Sabine , Vogel Markus , Russo Katie , Seiss Katherine , Tschantz William R. , Rejtar Tomas , Ruddy David A. , Hu Tiancen , Aardalen Kimberly , Wagner Joel P. , Dranoff Glenn , D'Alessio Joseph A.
Published: April 2023

Table S1
Table S4 from Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas
Authors: Bockmayr Michael , Klauschen Frederick , Maire Cecile L. , Rutkowski Stefan , Westphal Manfred , Lamszus Katrin , Schüller Ulrich , Mohme Malte
Published: April 2023

Stratified survival analysis of immune, stromal and functional signatures as well as immune checkpoint molecules.
Supplementary Figure Legend from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Authors: Pavlick Anna , Blazquez Ana B. , Meseck Marcia , Lattanzi Michael , Ott Patrick A. , Marron Thomas U. , Holman Rose Marie , Mandeli John , Salazar Andres M. , McClain Christopher B. , Gimenez Gustavo , Balan Sreekumar , Gnjatic Sacha , Sabado Rachel Lubong , Bhardwaj Nina
Published: April 2023

Descriptions of Supplementary Figures 1, 2, and 3, and supplementary table 1
Supplementary Fig 3 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Authors: Pavlick Anna , Blazquez Ana B. , Meseck Marcia , Lattanzi Michael , Ott Patrick A. , Marron Thomas U. , Holman Rose Marie , Mandeli John , Salazar Andres M. , McClain Christopher B. , Gimenez Gustavo , Balan Sreekumar , Gnjatic Sacha , Sabado Rachel Lubong , Bhardwaj Nina
Published: April 2023

Supplementary Fig 3
Supplementary Fig 1 from Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Authors: Pavlick Anna , Blazquez Ana B. , Meseck Marcia , Lattanzi Michael , Ott Patrick A. , Marron Thomas U. , Holman Rose Marie , Mandeli John , Salazar Andres M. , McClain Christopher B. , Gimenez Gustavo , Balan Sreekumar , Gnjatic Sacha , Sabado Rachel Lubong , Bhardwaj Nina
Published: April 2023

Supplementary Fig 1
Figure S2 from Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Authors: Liang Jiyong , Wang Lulu , Wang Chao , Shen Jianfeng , Su Bojin , Marisetty Anantha L. , Fang Dexing , Kassab Cynthia , Jeong Kang Jin , Zhao Wei , Lu Yiling , Jain Abhinav K. , Zhou Zhicheng , Liang Han , Sun Shao-Cong , Lu Changming , Xu Zhi-Xiang , Yu Qinghua , Shao Shan , Chen XiaoHua , Gao Meng , Claret Francois X. , Ding Zhiyong , Chen Jian , Chen Pingsheng , Barton Michelle C. , Peng Guang , Mills Gordon B. , Heimberger Amy B.
Published: April 2023

Supplemental Figure S2
Figure S1 from Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Authors: Liang Jiyong , Wang Lulu , Wang Chao , Shen Jianfeng , Su Bojin , Marisetty Anantha L. , Fang Dexing , Kassab Cynthia , Jeong Kang Jin , Zhao Wei , Lu Yiling , Jain Abhinav K. , Zhou Zhicheng , Liang Han , Sun Shao-Cong , Lu Changming , Xu Zhi-Xiang , Yu Qinghua , Shao Shan , Chen XiaoHua , Gao Meng , Claret Francois X. , Ding Zhiyong , Chen Jian , Chen Pingsheng , Barton Michelle C. , Peng Guang , Mills Gordon B. , Heimberger Amy B.
Published: April 2023

Supplemental Figure S1
Supplementary Figures from Human NKp44+ Group 3 Innate Lymphoid Cells Associate with Tumor-Associated Tertiary Lymphoid Structures in Colorectal Cancer
Authors: Ikeda Atsuyo , Ogino Takayuki , Kayama Hisako , Okuzaki Daisuke , Nishimura Junichi , Fujino Shiki , Miyoshi Norikatsu , Takahashi Hidekazu , Uemura Mamoru , Matsuda Chu , Yamamoto Hirofumi , Takeda Kiyoshi , Mizushima Tsunekazu , Mori Masaki , Doki Yuichiro
Published: April 2023

Supplementary figures S1-7
Figure S4 from Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages toward an Inflammatory Protumor Phenotype
Authors: Paolini Léa , Adam Clément , Beauvillain Céline , Preisser Laurence , Blanchard Simon , Pignon Pascale , Seegers Valérie , Chevalier Louise-Marie , Campone Mario , Wernert Romuald , Verrielle Véronique , Raro Pedro , Ifrah Norbert , Lavoué Vincent , Descamps Philippe , Morel Alain , Catros Véronique , Tcherkez Guillaume , Lenaers Guy , Bocca Cinzia , Kouassi Nzoughet Judith , Procaccio Vincent , Delneste Yves , Jeannin Pascale
Published: April 2023

Figure S4
Figure S4 from Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer
Authors: Anderson Kristin G. , Voillet Valentin , Bates Breanna M. , Chiu Edison Y. , Burnett Madison G. , Garcia Nicolas M. , Oda Shannon K. , Morse Christopher B. , Stromnes Ingunn M. , Drescher Charles W. , Gottardo Raphael , Greenberg Philip D.
Published: April 2023

Figure S4: Deep transcriptome profiling of ID8VEGF and HGSOC tumors reveals very similar gene expression profiles.
Table S10 from Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer
Authors: Aoki Hiroyasu , Ueha Satoshi , Shichino Shigeyuki , Ogiwara Haru , Shitara Kohei , Shimomura Manami , Suzuki Toshihiro , Nakatsura Tetsuya , Yamashita Makiko , Kitano Shigehisa , Kuroda Sakiko , Wakabayashi Masashi , Kurachi Makoto , Ito Satoru , Doi Toshihiko , Matsushima Kouji
Published: April 2023

Supplementary Table 10
Supplementary Figures 1-7, Supplementary Tables 1-8, 12 from Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer
Authors: Aoki Hiroyasu , Ueha Satoshi , Shichino Shigeyuki , Ogiwara Haru , Shitara Kohei , Shimomura Manami , Suzuki Toshihiro , Nakatsura Tetsuya , Yamashita Makiko , Kitano Shigehisa , Kuroda Sakiko , Wakabayashi Masashi , Kurachi Makoto , Ito Satoru , Doi Toshihiko , Matsushima Kouji
Published: April 2023

Supplementary Figures 1-7 Supplementary Table 1-8, 12
Supplementary Data from Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
Authors: Batra Sai Arun , Rathi Purva , Guo Linjie , Courtney Amy N. , Fleurence Julien , Balzeau Julien , Shaik Rahamthulla S. , Nguyen Thao P. , Wu Meng-Fen , Bulsara Shaun , Mamonkin Maksim , Metelitsa Leonid S. , Heczey Andras
Published: April 2023

Supplementary figures
Supplementary Figures and Table from Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
Authors: Phadke Manali S. , Chen Zhihua , Li Jiannong , Mohamed Eslam , Davies Michael A. , Smalley Inna , Duckett Derek R. , Palve Vinayak , Czerniecki Brian J. , Forsyth Peter A. , Noyes David , Adeegbe Dennis O. , Eroglu Zeynep , Nguyen Kimberly T. , Tsai Kenneth Y. , Rix Uwe , Burd Christin E. , Chen Yian A. , Rodriguez Paulo C. , Smalley Keiran S.M.
Published: April 2023

S1: IT monotherapy in SW1 model S2: IT->dabrafenib-trametinib therapy in BRAF mutant melanoma. S3: IT->TT sequence in NRAS#5 model S4: Expanded heatmap of all immune cells S5: IT->TT increases accumulation of activated CD8+ T cells S6: The TT->IT sequence on T cells, Tregs and MDSCS S7: Expanded heatmap of T and NK cells S8: IT->TT increases accumulation of activated CD8+ T cells, pathway analysis. S9: Expanded heatmap of myeloid cell data S10: IT->TT sequence increases expression of MHC I mRNAs S11: TT affects melanoma antigens S12: IC50 curves showing resistance to TT S13: Model showing mechanism of IT->TT sequence ST1: tumor weights at the end of the experiment
Supplementary Tables 1-2 and Figures 1-10 from Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
Authors: Schramme Florence , Crosignani Stefano , Frederix Kim , Hoffmann Delia , Pilotte Luc , Stroobant Vincent , Preillon Julie , Driessens Gregory , Van den Eynde Benoit J.
Published: April 2023

Supplementary tables and figures
Supplementary Figures and Tables from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma
Authors: Eom Jennifer , Park Saem Mul , Feisst Vaughan , Chen Chun-Jen J. , Mathy Joanna E. , McIntosh Julie D. , Angel Catherine E. , Bartlett Adam , Martin Richard , Mathy Jon A. , Cebon Jonathan S. , Black Michael A. , Brooks Anna E.S. , Dunbar P. Rod
Published: April 2023

Supplementary Figures 1-6 and Tables 1-7
Supplementary Data from γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival
Authors: Gherardin Nicholas A. , Waldeck Kelly , Caneborg Alex , Martelotto Luciano G. , Balachander Shiva , Zethoven Magnus , Petrone Pasquale M. , Pattison Andrew , Wilmott James S. , Quiñones-Parra Sergio M. , Rossello Fernando , Posner Atara , Wong Annie , Weppler Alison M. , Shannon Kerwin F. , Hong Angela , Ferguson Peter M. , Jakrot Valerie , Raleigh Jeanette , Hatzimihalis Athena , Neeson Paul J. , Deleso Paolo , Johnston Meredith , Chua Margaret , Becker Juergen C. , Sandhu Shahneen , McArthur Grant A. , Gill Anthony J. , Scolyer Richard A. , Hicks Rodney J. , Godfrey Dale I. , Tothill Richard W.
Published: April 2023

RNA-seq and scRNA-seq count data and TCR contigs
Figure S1 from Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Authors: De Martino Mara , Daviaud Camille , Diamond Julie M. , Kraynak Jeffrey , Alard Amandine , Formenti Silvia C. , Miller Lance D. , Demaria Sandra , Vanpouille-Box Claire
Published: April 2023

Gating strategy of intratumoral CD8+ T cells.
Supplementary Tables from Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas
Authors: Jing Lichen , Ott Mariliis , Church Candice D. , Kulikauskas Rima M. , Ibrani Dafina , Iyer Jayasri G. , Afanasiev Olga K. , Colunga Aric , Cook Maclean M. , Xie Hong , Greninger Alexander L. , Paulson Kelly G. , Chapuis Aude G. , Bhatia Shailender , Nghiem Paul , Koelle David M.
Published: April 2023

Sup Tables 1-6
Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy
Authors: Becker-Hapak Michelle K. , Shrestha Niraj , McClain Ethan , Dee Michael J. , Chaturvedi Pallavi , Leclerc Gilles M. , Marsala Lynne I. , Foster Mark , Schappe Timothy , Tran Jennifer , Desai Sweta , Neal Carly C. , Pence Patrick , Wong Pamela , Wagner Julia A. , Russler-Germain David A. , Zhu Xiaoyun , Spanoudis Catherine M. , Gallo Victor L. , Echeverri Christian A. , Ramirez Laritza L. , You Lijing , Egan Jack O. , Rhode Peter R. , Jiao Jin-an , Muniz Gabriela J. , Jeng Emily K. , Prendes Caitlin A. , Sullivan Ryan P. , Berrien-Elliott Melissa M. , Wong Hing C. , Fehniger Todd A.
Published: April 2023

Table 5 Excel Document
Figure S6 from Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer
Authors: Conti Laura , Bolli Elisabetta , Di Lorenzo Antonino , Franceschi Valentina , Macchi Francesca , Riccardo Federica , Ruiu Roberto , Russo Luca , Quaglino Elena , Donofrio Gaetano , Cavallo Federica
Published: April 2023

Figure S6
Figure S5 from Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer
Authors: Conti Laura , Bolli Elisabetta , Di Lorenzo Antonino , Franceschi Valentina , Macchi Francesca , Riccardo Federica , Ruiu Roberto , Russo Luca , Quaglino Elena , Donofrio Gaetano , Cavallo Federica
Published: April 2023

Figure S5
Supplementary Figure from Phosphoantigen-Stimulated γδ T Cells Suppress Natural Killer–Cell Responses to Missing-Self
Authors: Walwyn-Brown Katherine , Pugh Jason , Cocker Alexander T.H. , Beyzaie Niassan , Singer Bernhard B. , Olive Daniel , Guethlein Lisbeth A. , Parham Peter , Djaoud Zakia
Published: April 2023

Supplementary Figure from Phosphoantigen-Stimulated γδ T Cells Suppress Natural Killer–Cell Responses to Missing-Self
Supplementary Data from Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer
Authors: Dyugay Ilya A. , Lukyanov Daniil K. , Turchaninova Maria A. , Serebrovskaya Ekaterina O. , Bryushkova Ekaterina A. , Zaretsky Andrew R. , Khalmurzaev Oybek , Matveev Vsevolod B. , Shugay Mikhail , Shelyakin Pavel V. , Chudakov Dmitriy M.
Published: April 2023

Supplementary Data from Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer
Supplementary Data from High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation
Authors: Gao Qun , Wang Shumin , Li Feng , Lian Jingyao , Cheng Shaoyan , Yue Dongli , Zhang Zhen , Liu Shasha , Ren Feifei , Zhang Daiqun , Wang Shengdian , Wang Liping , Zhang Yi
Published: April 2023

Supplementary Data from High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation
Movie 4 from Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery
Authors: Slaats Jeroen , Dieteren Cindy E. , Wagena Esther , Wolf Louis , Raaijmakers Tonke K. , van der Laak Jeroen A. , Figdor Carl G. , Weigelin Bettina , Friedl Peter
Published: April 2023

OT-I CTL engaging with a MEC1/OVA target cell followed by target cell rounding and cell death in the absence (DMSO) or presence of BTP2. Time stamp, h:min. Scale bar, 10 µm.
Supplementary Figure Legends from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer
Authors: Ji Niannian , Mukherjee Neelam , Shu Zhen-Ju , Reyes Ryan M. , Meeks Joshua J. , McConkey David J. , Gelfond Jonathan A. , Curiel Tyler J. , Svatek Robert S.
Published: April 2023

Legends for all 7 supplementary figures
Table S1 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Authors: Lin Jianhuang , Guo Dajiang , Liu Heng , Zhou Wei , Wang Chen , Müller Iris , Kossenkov Andrew V. , Drapkin Ronny , Bitler Benjamin G. , Helin Kristian , Zhang Rugang
Published: April 2023

Table S1 shows the results of A CRISPR/Cas9 screen for chromatin regulators of PD-L1 expression
Supplementary Table 1 from CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1
Authors: Kantari-Mimoun Chahrazade , Barrin Sarah , Vimeux Lene , Haghiri Sandrine , Gervais Claire , Joaquina Sandy , Mittelstaet Joerg , Mockel-Tenbrinck Nadine , Kinkhabwala Ali , Damotte Diane , Lupo Audrey , Sibony Mathilde , Alifano Marco , Dondi Elisabetta , Bercovici Nadège , Trautmann Alain , Kaiser Andrew D. , Donnadieu Emmanuel
Published: April 2023

Antibodies used in MACSima
Movie S7 from CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1
Authors: Kantari-Mimoun Chahrazade , Barrin Sarah , Vimeux Lene , Haghiri Sandrine , Gervais Claire , Joaquina Sandy , Mittelstaet Joerg , Mockel-Tenbrinck Nadine , Kinkhabwala Ali , Damotte Diane , Lupo Audrey , Sibony Mathilde , Alifano Marco , Dondi Elisabetta , Bercovici Nadège , Trautmann Alain , Kaiser Andrew D. , Donnadieu Emmanuel
Published: April 2023

Distribution and migration and EGFR CAR T cells in a vibratome section of a human lung tumor
Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Authors: Cabo Mariona , Santana-Hernández Sara , Costa-Garcia Marcel , Rea Anna , Lozano-Rodríguez Roberto , Ataya Michelle , Balaguer Francesc , Juan Manel , Ochoa Maria C. , Menéndez Silvia , Comerma Laura , Rovira Ana , Berraondo Pedro , Albanell Joan , Melero Ignacio , López-Botet Miguel , Muntasell Aura
Published: April 2023

Figures S1, S2, S3, S4, S5, S6
Supplementary Table from P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy
Authors: Wanhainen Kelsey M. , Peng Changwei , Zhou Maggie H. , Macedo Bruna de Gois , O'Flanagan Stephen , Yang Tingyuan , Kelekar Ameeta , Burbach Brandon J. , Borges da Silva Henrique , Jameson Stephen C.
Published: April 2023

Supplementary Table from P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy
Supplementary Data from Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
Authors: Basu Amrita , Albert Gabriella K. , Awshah Sabrina , Datta Jashodeep , Kodumudi Krithika N. , Gallen Corey , Beyer Amber , Smalley Keiran S.M. , Rodriguez Paulo C. , Duckett Derek R. , Forsyth Peter A. , Soyano Aixa , Koski Gary K. , Lima Barros Costa Ricardo , Han Heather , Soliman Hatem , Lee Marie Catherine , Kalinski Pawel , Czerniecki Brian J.
Published: April 2023

Supplementary Data from Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
Supplementary Data from Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Authors: Blanco Belén , Ramírez-Fernández Ángel , Bueno Clara , Argemí-Muntadas Lidia , Fuentes Patricia , Aguilar-Sopeña Óscar , Gutierrez-Agüera Francisco , Zanetti Samanta Romina , Tapia-Galisteo Antonio , Díez-Alonso Laura , Segura-Tudela Alejandro , Castellà Maria , Marzal Berta , Betriu Sergi , Harwood Seandean L. , Compte Marta , Lykkemark Simon , Erce-Llamazares Ainhoa , Rubio-Pérez Laura , Jiménez-Reinoso Anaïs , Domínguez-Alonso Carmen , Neves Maria , Morales Pablo , Paz-Artal Estela , Guedan Sonia , Sanz Laura , Toribio María L. , Roda-Navarro Pedro , Juan Manel , Menéndez Pablo , Álvarez-Vallina Luis
Published: April 2023

Supplementary Data from Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Supplementary Figure from Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal
Authors: Hong Fang , Meng Qianqian , Zhang Weiyu , Zheng Ruiqin , Li Xiaoyun , Cheng Tao , Hu Deqing , Gao Xin
Published: April 2023

Supplementary Figure from Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal
Supplementary Table S1 from BET Inhibition Enhances TNF-Mediated Antitumor Immunity
Authors: Wellinger Lisa C. , Hogg Simon J. , Newman Dane M. , Friess Thomas , Geiss Daniela , Michie Jessica , Ramsbottom Kelly M. , Bacac Marina , Fauti Tanja , Marbach Daniel , Jarassier Laura , Thienger Phillip , Paehler Axel , Cluse Leonie A. , Kearney Conor J. , Vervoort Stephin J. , Trapani Joseph A. , Oliaro Jane , Shortt Jake , Ruefli-Brasse Astrid , Rohle Daniel , Johnstone Ricky W.
Published: April 2023

Cell lines used in this study.
Supplementary Table 2 from β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection
Authors: Guenther Carla , Faisal Imrul , Fusciello Manlio , Sokolova Maria , Harjunpää Heidi , Ilander Mette , Tallberg Robert , Vartiainen Maria Kristina , Alon Ronen , Gonzalez-Granado Jose-Maria , Cerullo Vincenzo , Fagerholm Susanna Carola
Published: April 2023

Supplementary Table 2
Supplementary Figures from β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection
Authors: Guenther Carla , Faisal Imrul , Fusciello Manlio , Sokolova Maria , Harjunpää Heidi , Ilander Mette , Tallberg Robert , Vartiainen Maria Kristina , Alon Ronen , Gonzalez-Granado Jose-Maria , Cerullo Vincenzo , Fagerholm Susanna Carola
Published: April 2023

Supplementary Figures 1-10
Supplementary Data from Tumor Necrosis Factor-α–Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer
Authors: Lou Yunwei , Song Miaomiao , Han Meijuan , Zhong Jiateng , Tian Xueqin , Ren Yahan , Song Yaru , Duan Liangwei , Zhao Peiqing , Song Xiangfeng , Zhang Wen , Chen Youhai H. , Wang Hui
Published: April 2023

Supplementary Data from Tumor Necrosis Factor-α–Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer
Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Authors: Wanderley Carlos Wagner S. , Maganin Alexandre G.M. , Adjafre Beatriz , Mendes Atlante S. , Silva Conceição Elidianne Anibal , Quadros Andreza Urba , Luiz João Paulo Mesquita , Silva Camila Meirelles S. , Silva Nicole R. , Oliveira Francisco Fabio Bezerra , Gomes Francisco Isaac F. , Restrepo Jeferson Leandro J. , Speck-Hernandez Cesar A. , Turaça Fernanda , Silva Gabriel Victor Lucena , Pigatto Glauce R. , Nakaya Helder I. , Mota Jose Mauricio , Barroso-Sousa Romualdo , Alves-Filho José C. , Cunha Thiago M. , Cunha Fernando Q.
Published: April 2023

Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling
Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Authors: Sánchez-Paulete Alfonso R. , Mateus-Tique Jaime , Mollaoglu Gurkan , Nielsen Sebastian R. , Marks Adam , Lakshmi Ashwitha , Khan Jalal A. , Wilk C. Matthias , Pia Luisanna , Baccarini Alessia , Merad Miriam , Brown Brian D.
Published: April 2023

Supplementary Figure from Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Supplementary Table from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
Authors: Hesterberg Rebecca S. , Liu Min , Elmarsafawi Aya G. , Koomen John M. , Welsh Eric A. , Hesterberg Stephen G. , Ranatunga Sujeewa , Yang Chunying , Li Weimin , Lawrence Harshani R. , Rodriguez Paulo C. , Berglund Anders E. , Cleveland John L.
Published: April 2023

Supplementary Table from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
Supplementary Figure from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
Authors: Hesterberg Rebecca S. , Liu Min , Elmarsafawi Aya G. , Koomen John M. , Welsh Eric A. , Hesterberg Stephen G. , Ranatunga Sujeewa , Yang Chunying , Li Weimin , Lawrence Harshani R. , Rodriguez Paulo C. , Berglund Anders E. , Cleveland John L.
Published: April 2023

Supplementary Figure from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
Supplementary Figure from Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy
Authors: Im Nam Gyu , Guillaumet-Adkins Amy , Wal Megha , Rogers Anna J. , Frede Julia , Havig Claire C. , Yang Jing , Anand Praveen , Stegmann Sarah K. , Waldschmidt Johannes M. , Sotudeh Noori , Niu Leili , Voisine Jordan , Schweiger Michal R. , Grassberger Clemens , Lohr Jens G. , Knoechel Birgit
Published: April 2023

Supplementary Figure from Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy
Supplementary Figure from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Authors: Bugatti Mattia , Bergamini Marco , Missale Francesco , Monti Matilde , Ardighieri Laura , Pezzali Irene , Picinoli Sara , Caronni Nicoletta , Missolo-Koussou Yoann , Helft Julie , Benvenuti Federica , Vermi William
Published: April 2023

Supplementary Figure from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Data from Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy
Authors: Im Nam Gyu , Guillaumet-Adkins Amy , Wal Megha , Rogers Anna J. , Frede Julia , Havig Claire C. , Yang Jing , Anand Praveen , Stegmann Sarah K. , Waldschmidt Johannes M. , Sotudeh Noori , Niu Leili , Voisine Jordan , Schweiger Michal R. , Grassberger Clemens , Lohr Jens G. , Knoechel Birgit
Published: April 2023

Supplementary Data from Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy
Supplementary Data from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Authors: Janku Filip , Han Sae-Won , Doi Toshihiko , Amatu Alessio , Ajani Jaffer A. , Kuboki Yasutoshi , Cortez Alex , Cellitti Susan E. , Mahling Ping C. , Subramanian Kulandayan , Schoenfeld Heidi A. , Choi Sarah M. , Iaconis Lori A. , Lee Lang Ho , Pelletier Marc R. , Dranoff Glenn , Askoxylakis Vasileios , Siena Salvatore
Published: April 2023

Supplementary Data from Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Supplementary Figure from Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors
Authors: Feng Tzu-Yu , Azar Francesca N. , Dreger Sally A. , Rosean Claire Buchta , McGinty Mitchell T. , Putelo Audrey M. , Kolli Sree H. , Carey Maureen A. , Greenfield Stephanie , Fowler Wesley J. , Robinson Stephen D. , Rutkowski Melanie R.
Published: April 2023

Supplementary Figure from Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors
Supplementary Data from Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells
Authors: Juras Patrick K. , Racioppi Luigi , Mukherjee Debarati , Artham Sandeep , Gao Xia , Akullian D'Agostino Laura , Chang Ching-Yi , McDonnell Donald P.
Published: April 2023

Supplementary Figures and Tables: 5 figures, 3 tables
Figure S1 from P. gingivalis Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer
Authors: Ren Junling , Han Xiao , Lohner Hannah , Hoyle Rosalie G. , Li Jiong , Liang Shuang , Wang Huizhi
Published: April 2023

Expression of DC surface markers and P. gingivalis W83-induced PD-L1
Table S2 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Authors: Han Tong , Wang Xujun , Shi Sailing , Zhang Wubing , Wang Jue , Wu Qiu , Li Ziyi , Fu Jingxin , Zheng Rongbin , Zhang Jiamin , Tang Qin , Zhang Peng , Wang Chenfei
Published: April 2023

Beta score (sheet1), mapping ratio (sheet2), and essential genes list (sheet3) of CRISPR screens.
Supplementary Figure Legends from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Authors: Veerman Rosanne E. , Akpinar Gözde Güclüler , Offens Annemarijn , Steiner Loïc , Larssen Pia , Lundqvist Andreas , Karlsson Mikael C.I. , Gabrielsson Susanne
Published: April 2023

Supplementary figure legends
Supplementary Figure 3 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Authors: Veerman Rosanne E. , Akpinar Gözde Güclüler , Offens Annemarijn , Steiner Loïc , Larssen Pia , Lundqvist Andreas , Karlsson Mikael C.I. , Gabrielsson Susanne
Published: April 2023

Gating strategy for MHCI+ and PD-L1+ tumor cells and intratumoral PD-1+ and pentamer+ T cells
Supplementary Figure 1 from Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Authors: Veerman Rosanne E. , Akpinar Gözde Güclüler , Offens Annemarijn , Steiner Loïc , Larssen Pia , Lundqvist Andreas , Karlsson Mikael C.I. , Gabrielsson Susanne
Published: April 2023

BMDC cell surface markers, and characterization of EVs from these cells, additional to Figure 1.
Figure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Authors: Schaafsma Evelien , Croteau Walburga , ElTanbouly Mohamed , Nowak Elizabeth C. , Smits Nicole C. , Deng Jie , Sarde Aurelien , Webber Cecilia A. , Rabadi Dina , Cheng Chao , Noelle Randolph , Lines J. Louise
Published: April 2023

Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.
Supplementary Tables from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
Authors: Pati Subhadip , Mukherjee Sumon , Dutta Saikat , Guin Aharna , Roy Dia , Bose Sayantan , Paul Silpita , Saha Sudipto , Bhattacharyya Sankar , Datta Pratyush , Chakraborty Jayati , Sarkar Diptendra K. , Sa Gaurisankar
Published: April 2023

Supplementary Tables S1-S6
Supplementary Figures 1-5 from Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer
Authors: Lidström Tommy , Cumming Joshua , Gaur Rahul , Frängsmyr Lars , Pateras Ioannis S. , Mickert Matthias J. , Franklin Oskar , Forsell Mattias N.E. , Arnberg Niklas , Dongre Mitesh , Patthey Cedric , Öhlund Daniel
Published: April 2023

Supplementary Figures 1-5
Table S7 from Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes
Authors: Hay Zachary L.Z. , Knapp Jennifer R. , Magallon Roman E. , O'Connor Brian P. , Slansky Jill E.
Published: April 2023

Intra cluster differential gene expression between Tet-High and Tet-Low cells
Supplementary Tables S1 - S5 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Authors: Pearce Hayden , Croft Wayne , Nicol Samantha M. , Margielewska-Davies Sandra , Powell Richard , Cornall Richard , Davis Simon J. , Marcon Francesca , Pugh Matthew R. , Fennell Éanna , Powell-Brett Sarah , Mahon Brinder S. , Brown Rachel M. , Middleton Gary , Roberts Keith , Moss Paul
Published: April 2023

Supplementary Tables 1 - 5
Supplementary Figures and Tables from Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer
Authors: He Kewen , Barsoumian Hampartsoum B. , Puebla-Osorio Nahum , Hu Yun , Sezen Duygu , Wasley Mark D. , Bertolet Genevieve , Zhang Jie , Leuschner Carola , Yang Liangpeng , Kettlun Leyton Claudia S. , Fowlkes Natalie Wall , Green Morgan Maureen , Hettrick Lisa , Chen Dawei , Masrorpour Fatemeh , Gu Meidi , Maazi Hadi , Revenko Alexey S. , Cortez Maria Angelica , Welsh James W.
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment
Authors: Garmendia Irati , Varthaman Aditi , Marmier Solenne , Angrini Mahmud , Matchoua Ingrid , Darbois-Delahousse Aurelie , Josseaume Nathalie , Foy Pierre-Emmanuel , Roumenina Lubka T. , Naouar Naïra , Meylan Maxime , Sibéril Sophie , Russick Jules , Joubert Pierre-Emmanuel , Leroy Karen , Damotte Diane , Mansuet-Lupo Audrey , Wislez Marie , Alifano Marco , Menger Laurie , Garcia-Verdugo Ignacio , Sallenave Jean-Michel , Lantz Olivier , Petitprez Florent , Cremer Isabelle
Published: April 2023

Supplementary data file
Supplementary Legends from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
Authors: Yan Bo , Hooper D. Craig , Yuan Zhiyong , Wang Changli , Chen Yulong , Lu Bo
Published: April 2023

legends for supplementary data
Supplementary Figure 2 from Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade
Authors: Yan Bo , Hooper D. Craig , Yuan Zhiyong , Wang Changli , Chen Yulong , Lu Bo
Published: April 2023

Supplementary Figure 2
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Authors: Zheng Hong , Yu Xiaoqing , Ibrahim Mohammed L. , Foresman Dana , Xie Mengyu , Johnson Joseph O. , Boyle Theresa A. , Ruffell Brian , Perez Bradford A. , Antonia Scott J. , Ready Neal , Saltos Andreas N. , Cantwell Mark J. , Beg Amer A.
Published: April 2023

Supplementary Table 3
Data from Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome
Authors: Vescovi Raffaella , Monti Matilde , Moratto Daniele , Paolini Lucia , Consoli Francesca , Benerini Luisa , Melocchi Laura , Calza Stefano , Chiudinelli Mariella , Rossi Giulio , Bugatti Mattia , Maio Michele , Fonsatti Ester , Farisoglio Camillo , Simbolo Michele , Almici Camillo , Verardi Rosanna , Scarpa Aldo , Bergese Paolo , Manganoni Ausilia , Facchetti Fabio , Vermi William
Published: April 2023

Abstract
Melanoma is an immunogenic neoplasm infiltrated by T cells, although these adaptive T cells usually fail to eradicate the tumor. Plasmacytoid dendritic cells (PDCs) are potent regulators of the adaptive immune response and can eliminate melanoma cells via TLR-mediated effector functions. The PDC compartment is maintained by progressively restricted bone marrow progenitors. Terminally differentiated PDCs exit the bone marrow into the circulation, then home to lymph nodes and inflamed peripheral tissues. Infiltration by PDCs is documented in various cancers. However, their role within the melanoma immune contexture is not completely known. We found that in locoregional primary cutaneous melanoma (PCM), PDC infiltration was heterogeneous, occurred early, and was recurrently localized at the invasive margin, the site where PDCs interact with CD8+ T cells. A reduced PDC density was coupled with an increased Breslow thickness and somatic mutations at the NRAS p.Q61 codon. Compared with what was seen in PCM, high numbers of PDCs were found in regional lymph nodes, as also identified by in silico analysis. In contrast, in metastatic melanoma patients, PDCs were mostly absent in the tumor tissues and were significantly reduced in the circulation, particularly in the advanced M1c group. Exposure of circulating PDCs to melanoma cell supernatant (SN-mel) depleted of extracellular vesicles resulted in significant PDC death. SN-mel exposure also resulted in a defect of PDC differentiation from CD34+ progenitors. These findings indicate that soluble components released by melanoma cells support the collapse of the PDC compartment, with clinical implications for refining TLR agonist–based trials.
Data from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer
Authors: Kibe Shiro , Yutani Shigeru , Motoyama Satoru , Nomura Takanobu , Tanaka Natsuki , Kawahara Akihiko , Yamaguchi Tomohiko , Matsueda Satoko , Komatsu Nobukazu , Miura Masatomo , Hinai Yudai , Hattori Satoshi , Yamada Akira , Kage Masayoshi , Itoh Kyogo , Akagi Yoshito , Sasada Tetsuro
Published: April 2023

Abstract
The prognosis of advanced colorectal cancer (aCRC) remains poor, and development of new therapeutic approaches, including immunotherapy, is needed urgently. Herein we report on our phase II study of personalized peptide vaccination (PPV) in 60 previously treated patients with aCRC, who had failed at least one regimen of standard chemotherapy and/or targeted therapy. For PPV, a maximum of four HLA-matched peptides were individually selected from a pool of 31 different peptide candidates based on preexisting host immunity, and administered subcutaneously without severe adverse events. Boosting of IgG and cytotoxic T lymphocyte (CTL) responses specific to the administered peptides was observed in 49% and 63%, respectively, of the patients, who completed the first cycles of six vaccinations. Median overall survival (OS) time was 498 days, with 1- and 2-year survival rates of 53% and 22%, respectively. Multivariate Cox regression analysis of prevaccination factors showed that plasma IL6, IP-10, and BAFF levels were significantly prognostic for OS [hazard ratio (HR), 1.508, P = 0.043; HR, 1.579, P = 0.024; HR, 0.509, P = 0.002, respectively]. In addition, increased peptide-specific CTL responses after vaccination were significantly predictive of favorable OS (HR, 0.231; P = 0.021), suggesting a causal relationship between biologic and clinical efficacy of PPV. On the basis of the safety profile and potential clinical efficacy, we believe that clinical trials of PPV would be warranted for previously treated patients with aCRC. Cancer Immunol Res; 2(12); 1154–62. ©2014 AACR.
Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Authors: Odunsi Kunle , Matsuzaki Junko , James Smitha R. , Mhawech-Fauceglia Paulette , Tsuji Takemasa , Miller Austin , Zhang Wa , Akers Stacey N. , Griffiths Elizabeth A. , Miliotto Anthony , Beck Amy , Batt Carl A. , Ritter Gerd , Lele Shashikant , Gnjatic Sacha , Karpf Adam R.
Published: April 2023

Abstract
The cancer–testis/cancer germline antigen, NY-ESO-1, is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase inhibitors may augment NY-ESO-1 vaccine therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Preclinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1–specific CTL-mediated responses. On the basis of these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 vaccine and doxorubicin liposome chemotherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T-cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in six of ten evaluable patients. On the basis of these encouraging results, evaluation of similar combinatorial chemo-immunotherapy regimens in EOC and other tumor types is warranted. Cancer Immunol Res; 2(1); 37–49. ©2014 AACR.
Data from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Authors: Richman Lee P. , Vonderheide Robert H.
Published: April 2023

Abstract
Agonists of the TNF superfamily of receptors hold promise as novel therapy for cancer. Recent data on agonistic antimurine TNF receptors (TNFR) such as CD40 suggest that the specific engagement of Fc receptor (FcR) is required for optimal antitumor effects, prompting calls to engineer antihuman CD40 and other TNFR monoclonal antibodies (mAb) accordingly. CP-870,893 is a fully human anti-CD40 mAb, selected in part because it is an immunoglobulin G2 (IgG2), which is presumed to have poor reactivity with FcR; however, CP-870,893 has been evaluated in multiple clinical trials with beneficial activity in patients with melanoma, pancreatic, and other cancers. Here, we confirmed that the activity of antimurine CD40 mAb was dependent on FcγRIIB engagement, was decreased significantly in FcγRIIB−/− mice, and upon Fc-crosslinking antimouse CD40 mAb enhanced the activation of antigen-presenting cells. In contrast, the CP-870,893-mediated activation of human B cells was not enhanced with anti-IgG crosslinking nor abrogated when used as an F(ab)′2 reagent. Crosslinking of CP-870,893 using the CD32-expressing K562 cells yielded an Fc-dependent modest increase in the expression of some activation markers relative to that of the soluble CP-870,893 mAb. Classic Fc-dependent functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CMC) were minimal for CP-870,893 as compared with the IgG1 anti-CD20 mAb rituximab, which mediated both ADCC and CMC in parallel assays. Antimouse CD40 mAb competed for the CD40 ligand binding site, but CP-870,893 did not. Thus, Fc crosslinking is not an essential requirement for agonistic antihuman CD40 mAbs, in which potency is more dependent on the CD40 epitope recognized and the strength of the signal achieved. Cancer Immunol Res; 2(1); 19–26. ©2013 AACR.
Data from Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
Authors: Galanina Natalie , Goodman Aaron M. , Cohen Philip R. , Frampton Garrett M. , Kurzrock Razelle
Published: April 2023

Abstract
Kaposi sarcoma (KS) is an incurable, human immunodeficiency virus (HIV)-associated malignancy. We reviewed 320 immunotherapy-treated patient records. Seventeen had HIV-associated malignancies, including nine men with KS. Median viral load was 20 copies/mL (range, undetectable to 549,704) and median CD4 count was 256 cells/μL (range, 10–603). Eight patients received nivolumab and one received pembrolizumab. Six patients (67%) achieved partial (N = 5) or complete remission (N = 1). No drug-related grade >2 toxicities occurred. In seven patients, CD4 counts increased (P = 0.09). Tissue and/or blood-derived circulating tumor DNA (ctDNA) was evaluated by next-generation sequencing. Four evaluable patients each showed anomalies in distinct genes: TP53, KRAS, TLL2, PTPN6 (tissue and/or ctDNA), and NF1 (ctDNA). Tumor mutational burden was low, and PD-L1 immunohistochemistry was negative (three and four assessable patients, respectively). Responders included patients with low CD4 counts, high HIV load, and/or visceral disease. In summary, checkpoint blockade demonstrated significant antitumor activity and low toxicity in patients with HIV-associated KS. Cancer Immunol Res; 6(10); 1129–35. ©2018 AACR.
Data from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Authors: Baumeister Susanne H. , Murad Joana , Werner Lillian , Daley Heather , Trebeden-Negre Helene , Gicobi Joanina K. , Schmucker Adam , Reder Jake , Sentman Charles L. , Gilham David E. , Lehmann Frédéric F. , Galinsky Ilene , DiPietro Heidi , Cummings Kristen , Munshi Nikhil C. , Stone Richard M. , Neuberg Donna S. , Soiffer Robert , Dranoff Glenn , Ritz Jerome , Nikiforow Sarah
Published: April 2023

Abstract
NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or poorly expressed on healthy tissues. We conducted a phase I dose-escalation study to evaluate the safety and feasibility of a single infusion of NKG2D-chimeric antigen receptor (CAR) T cells, without lymphodepleting conditioning in subjects with acute myeloid leukemia/myelodysplastic syndrome or relapsed/refractory multiple myeloma. Autologous T cells were transfected with a γ-retroviral vector encoding a CAR fusing human NKG2D with the CD3ζ signaling domain. Four dose levels (1 × 106–3 × 107 total viable T cells) were evaluated. Twelve subjects were infused [7 acute myeloid leukemia (AML) and 5 multiple myeloma]. NKG2D-CAR products demonstrated a median 75% vector-driven NKG2D expression on CD3+ T cells. No dose-limiting toxicities, cytokine release syndrome, or CAR T cell–related neurotoxicity was observed. No significant autoimmune reactions were noted, and none of the ≥ grade 3 adverse events were attributable to NKG2D-CAR T cells. At the single injection of low cell doses used in this trial, no objective tumor responses were observed. However, hematologic parameters transiently improved in one subject with AML at the highest dose, and cases of disease stability without further therapy or on subsequent treatments were noted. At 24 hours, the cytokine RANTES increased a median of 1.9-fold among all subjects and 5.8-fold among six AML patients. Consistent with preclinical studies, NKG2D-CAR T cell–expansion and persistence were limited. Manufactured NKG2D-CAR T cells exhibited functional activity against autologous tumor cells in vitro, but modifications to enhance CAR T-cell expansion and target density may be needed to boost clinical activity.